OncoMatch/Clinical Trials/NCT04796220
Focused Ultrasound and Gemcitabine in Breast Cancer
Is NCT04796220 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Focused Ultrasound for breast cancer.
Treatment: Focused Ultrasound — This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: HER2 (ERBB2) negative
Allowed: HER2 (ERBB2) positive
Allowed: ESR1 negative
Allowed: ESR1 positive
Allowed: PR (PGR) negative
Allowed: PR (PGR) positive
Disease stage
Required: Stage I, II, III
stage 1-3 disease and be appropriate surgical candidates for complete resection
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any treatment for current breast cancer
Received other treatment (standard or investigational) for their current breast cancer.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia · Charlottesville, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify